Invex approved to start Phase III idiopathic intracranial hypertension trial
The trial will analyse the safety and efficacy of Presendin compared to placebo in IIH patients over 24 weeks.
Therapy Area
Latest in
Therapy Area
Innovent Phase II ulcerative colitis antibody trial doses first subject
The trial is assessing the safety and efficacy of IBI112 to treat moderate-to-severe active UC.
Inhibrx concludes Phase I dose escalation of solid tumour therapy
The company received $60m from Oxford Finance under a Loan and Security Agreement.
Cara Therapeutics reports positive Phase II notalgia paresthetica trial
The oral difelikefalin group achieved the primary endpoint of change in the Worst Itch-Numeric Rating Scale score from baseline.
Sanofi Phase III tolebrutinib trials placed on partial hold by US FDA
The move comes after some cases of drug-induced liver injury were detected with tolebrutinib exposure in Phase III trials.
By
Ultimovacs Phase II melanoma trial concludes subject recruitment
The trial will analyse the combination therapy as a first-line treatment in advanced or metastatic malignant melanoma patients.
ADC Therapeutics begins dosing Phase Ib non-Hodgkin lymphoma study
The LOTIS-7 Phase Ib clinical trial will include multiple arms in dose escalation and dose expansion parts.
Ascentage Phase I cancer therapy trial receives FDA IND clearance
Dose-limiting toxicity, maximum tolerated dose and recommended Phase II dose of oral APG-5918 will be analysed in the trial.